about
(1)H NMR-based metabolic profiling of urinary tract infection: combining multiple statistical models and clinical data.Treatment duration of febrile urinary tract infection (FUTIRST trial): a randomized placebo-controlled multicenter trial comparing short (7 days) antibiotic treatment with conventional treatment (14 days)Hospitalization for community-acquired febrile urinary tract infection: validation and impact assessment of a clinical prediction rule.Urinary proteins, vitamin D and genetic polymorphisms as risk factors for febrile urinary tract infection and relation with bacteremia: a case control study.Treatment duration of febrile urinary tract infections.Procalcitonin reflects bacteremia and bacterial load in urosepsis syndrome: a prospective observational study.Treatment duration of febrile urinary tract infection: a pragmatic randomized, double-blind, placebo-controlled non-inferiority trial in men and womenFebrile urinary tract infection in the emergency room.Colistin: Revival of an Old Polymyxin Antibiotic.Effectiveness and cost-effectiveness of a nurse-delivered intervention to improve adherence to treatment for HIV: a pragmatic, multicentre, open-label, randomised clinical trial.[Clioquinol use for Dientamoeba fragilis infections is questionable].[Fosfomycin, an old antibiotic with new possibilities].Procoagulant tissue factor activity on microparticles is associated with disease severity and bacteremia in febrile urinary tract infections.Pelvic floor dysfunction is not a risk factor for febrile urinary tract infection in adults.Appendicitis Presenting As Cellulitis of the Right Leg.[Practical guideline for the use of colistin].Diabetes and the course of febrile urinary tract infection.Posaconazole prophylaxis in hematologic cancer.Fibrinogen alpha chain O-glycopeptides as possible markers of urinary tract infection.Capillary electrophoresis-time of flight-mass spectrometry using noncovalently bilayer-coated capillaries for the analysis of amino acids in human urine.Fosfomycin: Pharmacological, Clinical and Future Perspectives.Life-threatening acute lung injury after gamma butyrolactone ingestion.No human transmission ofMycobacterium malmoensein a perfect storm settingRisk Factors for Bacteremia with Uropathogen Not Cultured from Urine in Adults with Febrile Urinary Tract InfectionGather ye buds: fungus formation of the bladder after complicated cesarean sectionRe: Minardi et al.: The role of uroflowmetry biofeedback and biofeedback training of the pelvic floor muscles in the treatment of recurrent urinary tract infections in women with dysfunctional voiding: a randomized controlled prospective study (UrolRisk factors for fluoroquinolone-resistant Escherichia coli in adults with community-onset febrile urinary tract infectionProcalcitonin-based guidelines and lower respiratory tract infectionsShort course of intravenous antibiotics is as effective as longer course in infants with urinary tract infection
P50
Q30576794-C5E36B39-C4B3-4552-9499-45E96796EDD8Q33494958-7164E811-36CF-4CB3-B781-C85D149A85B3Q33771716-7A69B28D-4763-4EFB-B004-624E08F9CEDAQ35217225-806F709E-55D8-495A-83EC-A3821370AE3AQ35512218-A4E188EC-DE8D-4009-B232-F8F64507916AQ35561350-8ECBDE6E-3764-4D67-80F2-DFC8519AB85DQ36331082-6806BB3D-0B58-47F9-B738-0A9095ED9811Q38268770-F1F20F07-20D0-43B5-99DC-352AA658B9E7Q38303863-B19885DF-B884-49A8-9A17-9091D91E928FQ38927721-5E3E08FD-761D-4EAC-BC5C-FBB0F53A79E5Q40062953-2E24B0D2-7C31-4F7F-87B9-74AFD7266740Q40173284-CD278310-4AA0-40FE-BBEE-939A54B44516Q40213341-25A0FEBF-93AF-4BC0-94BD-9BEC78178158Q40374163-059E7A37-4A21-436E-965D-528A4062B4DCQ40530641-33B580F6-E702-4766-BD31-1C9CB384DD34Q41698282-1EE4B011-F760-4A97-A454-B1FE6A48C92CQ42855185-977F8B76-229D-4BF7-AEAE-9D95A13A5F69Q43581251-677B7566-F61F-4E95-A996-D22960835F46Q44669026-C1C4D446-5741-456C-8B67-0BE261E20ED8Q46584188-44402711-D610-40DD-897D-B25357FE7F21Q47136072-C89AE6FA-736F-4794-A3EB-CFC39C181E18Q50590837-921138E0-72B5-434A-B597-E6154315F71CQ57842302-11840542-189A-4122-9A2F-70F94810B322Q59688236-3CC6EB51-67D1-4913-A415-F8B4A69F759BQ61841527-4AF71ECD-1464-474E-A926-024E2B5CCEA1Q82343173-1255794B-2F1D-4EFC-A812-80B128458A7EQ82694773-D8CB44EA-9772-4842-8460-E9E2C8DE19D0Q82745776-C901245D-BF84-481D-BCAE-C11E74BE583AQ82825458-2BC63C7C-B91B-4252-BD14-E916EBB8D9D9
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Cees van Nieuwkoop
@ast
Cees van Nieuwkoop
@de
Cees van Nieuwkoop
@en
Cees van Nieuwkoop
@es
Cees van Nieuwkoop
@fr
Cees van Nieuwkoop
@nds
Cees van Nieuwkoop
@nl
Cees van Nieuwkoop
@sl
type
label
Cees van Nieuwkoop
@ast
Cees van Nieuwkoop
@de
Cees van Nieuwkoop
@en
Cees van Nieuwkoop
@es
Cees van Nieuwkoop
@fr
Cees van Nieuwkoop
@nds
Cees van Nieuwkoop
@nl
Cees van Nieuwkoop
@sl
prefLabel
Cees van Nieuwkoop
@ast
Cees van Nieuwkoop
@de
Cees van Nieuwkoop
@en
Cees van Nieuwkoop
@es
Cees van Nieuwkoop
@fr
Cees van Nieuwkoop
@nds
Cees van Nieuwkoop
@nl
Cees van Nieuwkoop
@sl
P106
P21
P31
P496
0000-0003-0734-0844